Fusion genes in solid tumors

Seminars in Cancer Biology

Volumn 9, Issue 4, 1999, Pages 303-318

  Aman, Pierre ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cancer; Chromosome translocation; DNA rearrangement; Fusion genes

Indexed keywords

PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

CANCER DIAGNOSIS; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; ENZYME ACTIVITY; FUSION GENE; GENE CONTROL; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; MESENCHYMOMA; NONHUMAN; PROMOTER REGION; RADIATION; REVIEW; SALIVARY GLAND TUMOR; SARCOMA; SOLID TUMOR; THYROID CARCINOMA;

EID: 0032846542     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1999.0130     Document Type: Article

References (150)

1. Klein G, Klein E. Evolution off tumors and the impact of molcular oncology. Nature. 315:1985;190-195.
2. Bishop JM. Molecular themes in oncogenesis. Cell. 64:1991;235-248.
3. Dong JT, Isaacs WB, Isaacs JT. Molecular advances in prostate cancer. Curr Opin Oncol. 9:1997;101-107.
4. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 319:1988;525-532.
5. Rabbitts T. Chromosomal translocations in human cancer. Nature. 372:1994;143-149.
6. Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S, Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer. 16:1996;1-14.
7. Pierotti MA, Santoro M, Jenkins RB, Sozzi G, Bongarzone I, Grieco M, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA. 89:1992;1616-1620.
8. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 10:1995;436-444.
9. Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations [published erratum appears in Nat Genet 1997 Apr;15(4):411]. Nat Genet. 15:1997;170-174.
10. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS, Seyama T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene. 15:1997;1455-1460.
11. de Klein A, van Agthoven T, Groffen C, Heisterkamp N, Groffen J, Grosveld G. Molecular analysis of both translocation products of a Philadelphia-positive CML patient. Nucl Acids Res. 14:1986;7071-7082.
12. Papadopoulos PC, Greenstein AM, Gaffney RA, Westbrook CA, Wiedemann LM. Characterization of the translocation breakpoint sequences in Philadelphia-positive acute lymphoblastic leukemia. Genes Chromosomes Cancer. 1:1990;233-239.
13. Krowczynska AM, Rudders RA, Krontiris TG. The human minisatellite consensus at breakpoints of oncogene translocations. Nucl Acids Res, 18:1990;1121-1127.
14. Jaeger U, Purtscher B, Karth GD, Knapp S, Mannhalter C, Lechner K. Mechanism of the chromosomal translocation t(14;18) in lymphoma: detection of a 45-kDa breakpoint binding protein. Blood. 81:1993;1833-1840.
15. Seite P, Hillion J, Leroux D, Berger R, Larsen CJ. Common sequence in chromosome translocations affecting B- and T-cell malignancies: a novel recombination site? [letter]. Genes Chromosomes Cancer. 6:1993;253-254.
16. Bae YS, Kawasaki I, Ikeda H, Liu LF. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA. 85:1988;2076-2080.
17. Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia. 9:1995;1305-1312.
18. Dong S, Geng JP, Tong JH, Wu Y, Cai JR, Sun GL, et al. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer. 6:1993;133-139.
19. Felix CA, Lange BJ, Hosler MR, Fertala J, Bjornsti MA. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res. 55:1995;4287-4292.
20. Aoki K, Suzuki K, Sugano T, Tasaka T, Nakahara K, Kuge O, et al. A novel gene, Translin, encodes a recombination hotspot binding protein associated with chromosomal translocations. Nat Genet. 10:1995;167-174.
21. Panagopoulos I, Lassen C, Mandahl N, Mitelman F, Åman P. Seq uence analysis of the breakpoints in myxoid liposarcomas with FUS-CHOP and EWS-CHOP hybrid genes and in an acute myeloid leukemia with a FUS-ERG hybrid gene. Oncogene. 15:1997;1357-1362.
22. Bhagirath T, Abe S, Nojima T, Yoshido MC. Molecular analysis of a t(11;22) translocation junction in a case of Ewing's sarcoma. Genes Chromosomes Cancer. 13:1995;126-132.
23. Spitzner JR, Chung IK, Muller MT. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res. 18:1989;1-11.
24. Kanoe H, Nakayama T, Hosaka T, Yamamoto H, Nakashima Y, Tsuboyama T, et al. Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation. Oncogene. 18:1999;721-729.
25. Chalk JG, Barr FG, Mitchell CD. Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines. Oncogene. 15:1997;1199-1205.
26. Liu J, Nau MM, Zucman Rossi J, Powell JI, Allegra CJ, Wright JJ. LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. Genes Chromosomes Cancer. 18:1997;232-239.
27. Kazmierczak B, Pohnke Y, Bullerdiek J. Fusion transcripts between the HMGIC gene and RTVL-H-related sequences in mesenchymal tumors without cytogenetic aberrations. Genomics. 38:1996;223-226.
28. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 15:1997;1263-1273.
29. Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res. 53:1993;2940-2943.
30. Bongarzone I, Butti MG, Fugazzola L, Pacini F, Pinchera A, Vorontsova TV, et al. Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics. 42:1997;252-259.
31. Turc-Carel C, Limon J, Dal Cin P, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16) (q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet. 23:1986;291-299.
32. Mandahl N, Mertens F, Åman P, Rydholm A, Brosjö O, Willén H, et al. Nonrandom secondary chromosome aberrations in liposarcomas with t(12;16). Int J Oncol. 4:1994;307-310.
33. Åman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer. 5:1992;278-285.
34. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 363:1993;640-836.
35. Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet. 4:1993;175-180.
36. Panagopoulos I, Mandahl N, Ron D, Hoglund M, Nilbert M, Mertens F, et al. Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation. Cancer Res. 54:1994;6500-6503.
37. Kuroda M, Ishida T, Horiuchi H, Kida N, Uozaki H, Takeuchi H, et al. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid liposarcoma. Am J Pathol. 147:1995;1221-1227.
38. Panagopoulos I, Åman P, Mandahl N, Mitelman F. Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). Oncogene. 11:1995;1133-1137.
39. Åman P, Panagopoulos I, Lassen C, Fioretos T, Mencinger M, Toresson H, et al. Expression patterns of the sarcoma associated genes FUS and EWS and the genomic structure pf FUS. Genomics. 37:1996;1-8.
40. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant negative inhibitor of gene transcription. Genes Dev. 6:1992;439-453.
41. Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol. 12:1998;4-18.
42. Calvio C, Neubauer G, Mann M, Lamond AI. Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry. Rna. 1:1995;724-733.
43. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci. 110:1997;1741-1750.
44. Zinszner H, Immanuel D, Yin Y, Liang FX, Ron D. A topogenic role for the oncogenic N-terminus of TLS: nucleolar localization when transcription is inhibited. Oncogene. 14:1997;451-461.
45. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 359:1992;162-165.
46. Panagopoulos I, Höglund M, Mertens F, Mandahl N, Mitelman F, Åman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 12:1996;489-494.
47. DalCin P, Sciot R, Panagopoulos I, Åman P, Samson I, Mandahl N, et al. Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma. J Pathol. 182:1997;437-441.
48. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 12:1993;4481-4487.
49. Sorensen PH, Lessnick SL, Lopez Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 6:1994;146-151.
50. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 10:1995;1229-1234.
51. Urano F, Umezawa A, Hong W, Kikuchi H, Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun. 219:1996;608.
52. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 14:1997;1159-1164.
53. Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman F, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 4:1993;341-345.
54. Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 54:1994;2837-2840.
55. Andersson H, Mandahl N, Meis Kindblom JM, Kindblom LG. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer. 62:1995;398-402.
56. Zucman J, Stenman G, Kindblom LG, Knight J, Turc Carel C, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet. 4:1995;2219-2226.
57. Benjamin H, Gill S, Sidhar S, Goodwin G, Crew J, et al. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene. 12:1996;229-235.
58. Ueda T, Hamelin A, Jhanwar SC, Bridge JA, Healey JH, et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. Am J Pathol. 150:1997;1049-1058.
59. Hoglund M, Mertens F, Mandahl N, Mitelman F, Aman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 12:1996;489-494.
60. Query CC, Keene JD. RNA recognition: towards identifying determinants of specificity. Trends Biochem Sci. 16:1991;214-220.
61. Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J. 17:1998;4442-4455.
62. Rabbitts TH. Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA. 91:1994;7869-8424.
63. Ouchida M, Lee L, Rao VN, Reddy ES. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene. 9:1994;3717-3729.
64. Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol. 14:1994;3230-3241.
65. Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 8:1994;2513-23526.
66. Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 7:1994;502-508.
67. Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet. 4:1995;1097-1099.
68. Clark J, Fisher C, Gill S, Grimer R, Chand A, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. Embo J. 14:1995;2333-2340.
69. Balemans M, Geurts van Kessel A. A novel Kruppel-associated box containing the SSX gene (SSX3) on the human X chromosome is not implicated in t(X;18)-positive synovial sarcomas. Cytogenet Cell Genet. 73:1996;179-183.
70. Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, Larson O. A novel fusion gene SYT-SSX4 in synovial sarcoma. J Natl Cancer Inst. 91:1999;974-975.
71. de Bruijn DR, Balemans M, Janssen B, Gartner F, Lop es JM, et al. Nuclear localization of SYT, SSX and the synovial sarcom a-associated SYT-SSX fusion proteins. Hum Mol Genet. 6:1997;1549-1558.
72. Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet. 6:1997;1559-1564.
73. Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJd, E manuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma [published erratum appears in Nat Genet 1994 Feb;6(2):214]. Nat Genet. 5:1993;230-235.
74. Jeon IS, Shapiro DN. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene. 11:1995;545-552.
75. Fredericks WJ, Wilson RB, Rauscher FJ, 3rd, Barr FG. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene. 11:1995;119-130.
76. Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol. 15:1995;1522-1535.
77. Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol. 18:1998;4118-4130.
78. Lacour JP, Perrin C, Huffermann K, Simon MP, Ayraud N, et al. Another case of t(17;22)(q22;q13) in an infantile dermatofibrosarcoma protuberans. Cancer Genet Cytogenet. 89:1996;175-176.
79. Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 15:1997;95-98.
80. Seroussi E, Dal Cin P, Sciot R, Mandahl N, Fletcher JA, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas [In Process Citation]. Genes Chromosomes Cancer. 23:1998;187-193.
81. Hoglund M, O'Brien KP, Dumanski JP, Mertens F, Mandahl N. A case of dermatofibrosarcoma protuberans with a ring chromosome 5 and a rearranged chromosome 22 containing amplified COL1A1 and PDGFB sequences. Cancer Lett. 133:1998;129-134.
82. Pierotti MA, Monzini N, Mondellini P, Manenti G, Donghi R, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene. 4:1989;1457-1462.
83. Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 60:1990;557-563.
84. Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 319:1986;743-748.
85. Mitra G, Long LK, Barbacid M. Molecular characterization of the human trk oncogene. Cold Spring Harbor Symp Quant Biol. 2:1986;983-992.
86. Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 328:1987;170-172.
87. Mitra G, Martin Zanca D, Barbacid M. Identification and biochem ical characterization of p70TRK, product of the human TRK oncogene. Proc Natl Acad Sci USA. 84:1987;6707-6711.
88. Kozma SC, Redmond SM, Fu XC, Saurer SM, Groner B, Hynes NE. Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences. EMBO J. 7:1988;147-154.
89. Grieco M, Santoro M, Berlingieri MT, Donghi R, Pierotti MA, Della Porta G, et al. Molecular cloning of PTC, a new oncogene found activated in human thyroid papillary carcinomas and their lymph node metastases. Ann NY Acad Sci. 551:1988;380-381.
90. Oskam R, Coulier F, Ernst M, Martin Zanca D, Barbacid M. Frequent generation of oncogenes by in vitro recombination of TRK protooncogene sequences. Proc Natl Acad Sci USA. 85:1988;2964.
91. Martin Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol. 9:1989;24-33.
92. Miozzo M, Pierotti MA, Sozzi G, Radice P, Bongarzone I, Spurr NK, et al. Human TRK proto-oncogene maps to chromosome 1q32-q41. Oncogene. 5:1990;1411-1414.
93. Coulier F, Kumar R, Ernst M, Klein R, Martin Zanca D, Barbacid M. Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol Cell Biol. 10:1990;4202-4210.
94. Sozzi G, Pierotti MA, Miozzo M, Donghi R, Radice P, De Benedetti V, et al. Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. Oncogene. 6:1991;339-342.
95. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest. 89:1992;1517-1522.
96. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C, Della Porta G. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene. 7:1992;237-242.
97. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 4:1998;223-228.
98. Sozzi G, Bongarzone I, Miozzo M, Borrello MG, Blutti MG, Pilotti S, et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer. 9:1994;244-250.
99. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 9:1994;509-516.
100. Fugazzola L, Pierotti MA, Vigano E, Pacini F, Vorontsova TV, Bongarzone I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene. 13:1996;1093-1097.
101. Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res. 58:1998;198-203.
102. Martin Zanca D, Barbacid M, Parada LF. Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev. 4:1990;683-694.
103. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 19:1997;112-123.
104. Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, et al. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol. 15:1995;6118-6127.
105. Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, et al. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene. 16:1998;809-816.
106. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA. Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene. 17:1998;1079-1087.
107. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol. 16:1996;2151-2163.
108. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer. 5:1992;278-2257.
109. Stenman G, Sahlin P, Mark J, Chaganti RS, Kindblom LG, Aman P. The 12q13-q15 translocation breakpoints in pleomorphic adenoma and clear-cell sarcoma of tendons and aponeuroses are different from that in myxoid liposarcoma. Genes Chromosomes Cancer. 7:1993;178-180.
110. Nilbert M, Mandahl N, Åman P, Rydholm A, Mitelman F. No rearrangements of the CHOP gene in malignant fibrous histiocytoma. Cancer Genet Cytogenet. 72:1994;155-156.
111. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C [see comments]. Nature. 376:1995;771-774.
112. Petit MMR, Mols R, Schoenmakers EF, Mandahl N, Van de Ven WJ. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics. 36:1996;118-129.
113. Schoenmakers EF, Huysmans C, Van de Ven WJ. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res. 59:1999;19-23.
114. Geurts JM, Schoenmakers EF, Roijer E, Astrom AK, Stenman G, van de Ven WJ. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene. 16:1998;865-872.
115. Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res. 57:1997;13-17.
116. Schoenberg Fejzo M, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremowicz S, et al. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer. 17:1996;1-6.
117. Kools PF, Van de Ven WJ. Amplification of a rearranged form of the high-mobility group protein gene HMGIC in OsA-CI osteosarcoma cells. Cancer Genet Cytogenet. 91:1996;1-7.
118. Geurts JM, Schoenmakers EF, Van de Ven WJ. Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3′-UTR of HMGIC. Cancer Genet Cytogenet. 95:1997;198-205.
119. Wanschura S, Dal Cin P, Kazmierczak B, Bartnitzke S, Van den Berghe H, Bullerdiek J. Hidden paracentric inversions of chromosome arm 12q affecting the HMGIC gene. Genes Chromosomes Cancer. 18:1997;322-323.
120. Gisselsson D, Andreasson P, Meis Kindblom JM, Kindblom LG, Mertens F, Mandahl N. Amplification of 12q13 and 12q15 sequences in a sclerosing epithelioid fibrosarcoma. Cancer Genet Cytogenet. 107:1998;102-106.
121. Berner JM, Meza Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, et al. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene. 14:1997;2935-2941.
122. Rogalla P, Drechsler K, Schroder Babo W, Eberhardt K, Bullerdiek J. HMGIC expression patterns in non-small lung cancer and surrounding tissue. Anticancer Res. 18:1998;3327-3330.
123. Dal Cin P, Wanschura S, Kazmierczak B, Tallini G, Dei Tos A, Bullerdi ek J, et al. Amplification and expression of the HMGIC gene in a benign endometrial polyp. Genes Chromosomes Cancer. 22:1998;95-99.
124. Kazmierczak B, Dal Cin P, Wanschura S, Borrmann L, Fusco A, Van den Berghe H, et al. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors [In Process Citation]. Genes Chromosomes Cancer. 23:1998;279-285.
125. Röijer E, Kas K, Behrendt M, Van de Ven W, Stenman G. Fluorescence in situ hybridization mapping of breakpoints in pleomorphic adenomas with 8q12-13 abnormalities identifies a subgroup of tumors without PLAG1 involvement [In Process Citation]. Genes Chromosomes Cancer. 24:1999;78-82.
126. Voz ML, Astrom AK, Kas K, Mark J, Stenman G, Van de Ven WJ. The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene. 16:1998;1409-1416.
127. Åström AK, Voz ML, Kas K, Roijer E, Wedell B, Mandahl N, et al. Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res. 59:1999;918-923.
128. Kas K, Voz ML, Hensen K, Meyen E, Van de Ven WJ. Transcriptional activation capacity of the novel PLAG family of zinc finger proteins. J Biol Chem. 273:1998;23026-23032.
129. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA. 90:1993;5752-5756.
130. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 13:1993;7393-7398.
131. Mao X, Miesfeldt S, Yang H, Leiden JM, Thompson CB. The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem. 269:1994;18216-18222.
132. Brown AD, Lopez Terrada D, Denny C, Lee KA. Promoters containing ATF-binding sites are de-regulated in cells that express the EWS/ATF1 oncogene. Oncogene. 10:1995;1749-1756.
133. Fujimura Y, Ohno T, Siddique H, Lee L, Rao VN, Reddy ES. The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. Oncogene. 12:1996;159-167.
134. Pan S, Ming KY, Dunn TA, Li KK, Lee KA. The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directly. Oncogene. 16:1998;1625-1631.
135. Li KK, Lee KA. MMSP tumor cells expressing the EWS/ATF1 oncogene do not support cAMP-inducible transcription. Oncogene. 16:1998;1325-1331.
136. Karnieli E, Werner H, Rauscher FJ 3rd, Benjamin LE, LeRoith D. The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem. 271:1996;19304-19309.
137. Kim J, Lee K, Pelletier J. The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct. Oncogene. 16:1998;1021-1030.
138. Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 17:1997;309-313.
139. Rao VN, Ohno T, Prasad DD, Bhattacharya G, Reddy ES. Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein. Oncogene. 8:1993;2167-2173.
140. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54:1994;2865-5472.
141. Panagopoulos I, Åman P, Fioretos T, Höglund M, Johansson B, Mandahl N, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer. 11:1994;256-262.
142. Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 8:1994;2513-2526.
143. Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 53:1993;5859-5863.
144. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: Interaction between two members of the TET family, EWS and hTAF(II)68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol. 18:1998;1489-1497.
145. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the proto-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 15:1996;5022-5031.
146. Thompson AD, Braun BS, Arvand A, Stewart SD, May WA, Chen E, et al. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene. 13:1996;2649-2658.
147. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 17:1997;495-497.
148. Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT. EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene. 17:1998;2039-2045.
149. Thelin-Jarnum S, Lassen C, Panagopoulos I, Mandahl N, Åman P. Indentification of genes differentially expressed in myxoid liposarcomas carrying a t(12;16) translocation. Int J Cancer, 1999.
150. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58:1998;5009-5013.